A medicine widely used to treat attention-deficit/hyperactivity disorder also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a trial led by St. Jude Children’s Research Hospital. Young cancer survivors performed better than unmedicated patients in tests of sustained attention and other measures related to attention, social skills, and behavior one year after they started methylphenidate. Heather Conklin, Ph.D. from the St. Jude Psychology Department, is the first to publish the research in the Journal of Clinical Oncology.
For more information, visit
5
t
